Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01804140 · ClinicalTrials.gov registry record
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 662
- Enrollment target
NCT01804140 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 662 participants.
The verdict
NCT01804140 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 662 participants
- Enrollment target
Study Summary
This is a screening study to detect BRAF V600 mutation-positive patients for enrollment into clinical research studies of Zelboraf (vemurafenib). Tumor samples will be collected and analyzed from eligible patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma. All institutions with identified patients as defined by this screening protocol will have potential access to the separate vemurafenib protocol MO28072.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 662 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01804140
The ClinicalTrials.gov registry entry for NCT01804140 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 662 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01804140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01804140 about?
NCT01804140 is a clinical study titled "A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)". This is a screening study to detect BRAF V600 mutation-positive patients for enrollment into clinical research studies of Zelboraf (vemurafenib). Tumor samples will be collected and analyzed from eligible patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or mult...
What is the current status of trial NCT01804140?
This trial is currently completed. The enrollment target is 662 participants. The study started on 2012-12. Estimated completion is 2013-09.
Who is sponsoring clinical trial NCT01804140?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.